Clinical Trials Logo

Clinical Trial Summary

This study will be a prospective, non-randomized evaluation of the Tritanium® Acetabular Shell for primary total hip replacement (THR) with a cementless application in a consecutive series of patients who meet the eligibility criteria. Half of the cases will use the X3® polyethylene insert alone as the bearing surface; the other half will use the MDM™ liner coupled with a compatible ADM/MDM™ X3® insert as the bearing surface. The success rate, defined as freedom from acetabular revision for any reason, for hips implanted with the Tritanium® Acetabular Shell, is no worse than for hips implanted with similar technology as reported in the literature and Trident® X3® Study historical control at 5 years postoperative.


Clinical Trial Description

The Tritanium® Acetabular Shell, cleared for use under FDA 510(k) K081171, is a hemispherical acetabular shell with a 3D surface for biological fixation, fabricated from Commercially Pure Titanium (CPTi). The shell is built upon the design features and clinical history of the existing Trident® Tritanium®, Trident® AD, and Trident® HA hemispherical acetabular shells. The device is designed with a roughened surface and high coefficient of friction to resist micromotion and promote initial fixation. The Tritanium® Acetabular Shell, intended for use in a cementless application, is available in sizes from 44 millimeter (mm) through 66 mm and is compatible with Trident® polyethylene liners and acetabular screws. This advanced technology is designed to address the need for improved initial and biological fixation. Data in support of these marketing claims will be collected in the Tritanium® Primary Acetabular Shell Study. A prospective, post-market, multi-center design will be employed. Radiographs will be assessed by an independent reviewer. Cases will be enrolled at 7 to 12 centers. The enrollment goal ranges from 20 to 34 cases implanted with the Tritanium® Acetabular Shell per center. The enrollment goal range is dependent upon the number of participating centers as well as the relative rates of enrollment of the two treatment groups. Although a range is presented, there is no maximum limit to the number of cases that a center may enroll. In the event that a center far exceeds the overall enrollment goal or enrollment into one of the treatment groups is completed, Stryker may ask the center to cease enrollment so as not to skew the data. All participating centers will comply with the federal regulations regarding patient informed consent and Institutional Review Board (IRB) approval. Non-compliance of a study center may result in termination of the center's participation in the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01063751
Study type Interventional
Source Stryker Orthopaedics
Contact
Status Active, not recruiting
Phase N/A
Start date July 2011
Completion date May 5, 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Recruiting NCT03746925 - Comparing Short-term Outcomes After Direct Anterior and SuperPATH Hip Arthroplasty Approaches N/A
Completed NCT03008967 - A Study of Patients Undergoing Total Knee and Hip Arthroplasty at a Regional Hospital in Denmark N/A
Not yet recruiting NCT00958945 - Retrospective Chart Analysis in the Effective Use of FloSeal in Post-Operative Joint Replacements N/A
Completed NCT00980616 - Use of Local Analgesia With Epinephrine During Total Hip Arthroplasty (THA) Phase 2
Completed NCT04542174 - PMCF 8 Year Results TRJ®
Not yet recruiting NCT04019925 - Assessing the Wear Rates of the ADM/MDM Hips Using 3D X-ray Analysis N/A
Recruiting NCT06102811 - Low Concentration Local Anesthesia Fascia Iliaca Block for Total Hip Arthroplasty N/A
Recruiting NCT03570944 - Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol (POWER2)
Recruiting NCT02938962 - Intravenous vs. Topical Tranexamic Acid in Revision THA (VITALITY-X) Phase 4
Completed NCT03076827 - Effects of Surgery Start Time on Postoperative Interleukin-6, Interleukin-8, and Cortisol N/A
Recruiting NCT02385383 - An Intravenous Iron Based Protocol for Preoperative Anaemia in Hip and Knee Surgery - An Observational Study N/A
Completed NCT01444586 - Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE) N/A
Terminated NCT02525627 - A Comparative Study of In-vivo Wear Between 28 mm and 40 mm Metal Heads N/A
Completed NCT00808483 - Walking Skill Training Program Effects in Patients With Total Hip Arthroplasty N/A
Terminated NCT00958347 - Omnifit Hydroxylapatite (HA) Hip Outcomes Study N/A
Completed NCT01422304 - Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038) Phase 3
Completed NCT04332055 - RCT Measuring the Effect of the ERVIN Software N/A
Completed NCT01257568 - Rejuvenate Modular Outcomes Study N/A
Recruiting NCT01031732 - Evaluation of Four Surgical Techniques in Primary Total Hip Arthroplasty N/A